



Secular Trends in Procedural Stroke or Death Risks of Stenting Versus Endarterectomy for Symptomatic Carotid Stenosis

Müller, Mandy D ; von Felten, Stefanie ; Algra, Ale ; Becquemin, Jean-Pierre ; Bulbulia, Richard ; Calvet, David ; Eckstein, Hans-Henning ; Fraedrich, Gustav ; Halliday, Alison ; Hendrikse, Jeroen ; Howard, George ; Gregson, John ; Jansen, Olav ; Brown, Martin M ; Mas, Jean-Louis ; Brott, Thomas G ; Ringleb, Peter A ; Bonati, Leo H

Abstract: **BACKGROUND** Over the past decades, stroke risk associated with carotid disease has decreased, reflecting improvements in medical therapy and a more rigorous control of vascular risk factors. It is less clear whether the procedural risk of carotid revascularization has declined over time. **METHODS** We analyzed temporal changes in procedural risks among 4597 patients with symptomatic carotid stenosis treated with carotid artery stenting (n=2326) or carotid endarterectomy (n=2271) in 4 randomized trials between 2000 and 2008, using generalized linear mixed-effects models with a random intercept for each source trial. Models were additionally adjusted for age and other baseline characteristics predicting treatment risk. The primary outcome event was any procedural stroke or death, occurring during or within 30 days after revascularization. **RESULTS** The procedural stroke or death risk decreased significantly over time in all patients (unadjusted odds ratio per year, 0.91; 95% CI, 0.85-0.97; P=0.006). This effect was driven by a decrease in the carotid endarterectomy group (unadjusted odds ratio per year, 0.82; 95% CI, 0.73-0.92; P=0.003), whereas no significant decrease was found after carotid artery stenting (unadjusted odds ratio, 0.96; 95% CI, 0.88-1.04; P=0.33). Carotid endarterectomy patients had a lower procedural stroke or death risk compared with carotid artery stenting patients, and the difference significantly increased over time (interaction P=0.031). After adjustment for baseline characteristics, the results remained essentially the same. **CONCLUSIONS** The risk of stroke or death associated with carotid endarterectomy for symptomatic carotid stenosis decreased over an 8-year period, independent of clinical predictors of procedural risk. No corresponding reduction in procedural risk was seen in patients treated with stenting. **CLINICAL TRIAL REGISTRATION** URL: <https://www.clinicaltrials.gov>; <http://www.isrctn.com>. Unique identifier: NCT00190398 (EVA-3S), NCT00004732 (CREST), ISRCTN57874028 (SPACE), and ISRCTN25337470 (ICSS).

DOI: <https://doi.org/10.1161/CIRCINTERVENTIONS.119.007870>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-177464>

Journal Article

Published Version

Originally published at:

Müller, Mandy D; von Felten, Stefanie; Algra, Ale; Becquemin, Jean-Pierre; Bulbulia, Richard; Calvet, David; Eckstein, Hans-Henning; Fraedrich, Gustav; Halliday, Alison; Hendrikse, Jeroen; Howard, George; Gregson, John; Jansen, Olav; Brown, Martin M; Mas, Jean-Louis; Brott, Thomas G; Ringleb, Peter A;

Bonati, Leo H (2019). Secular Trends in Procedural Stroke or Death Risks of Stenting Versus Endarterectomy for Symptomatic Carotid Stenosis. *Circulation. Cardiovascular Interventions*, 12(8):e007870.
DOI: <https://doi.org/10.1161/CIRCINTERVENTIONS.119.007870>

ORIGINAL ARTICLE

Secular Trends in Procedural Stroke or Death Risks of Stenting Versus Endarterectomy for Symptomatic Carotid Stenosis

A Pooled Analysis of Randomized Trials

BACKGROUND: Over the past decades, stroke risk associated with carotid disease has decreased, reflecting improvements in medical therapy and a more rigorous control of vascular risk factors. It is less clear whether the procedural risk of carotid revascularization has declined over time.

METHODS: We analyzed temporal changes in procedural risks among 4597 patients with symptomatic carotid stenosis treated with carotid artery stenting (n=2326) or carotid endarterectomy (n=2271) in 4 randomized trials between 2000 and 2008, using generalized linear mixed-effects models with a random intercept for each source trial. Models were additionally adjusted for age and other baseline characteristics predicting treatment risk. The primary outcome event was any procedural stroke or death, occurring during or within 30 days after revascularization.

RESULTS: The procedural stroke or death risk decreased significantly over time in all patients (unadjusted odds ratio per year, 0.91; 95% CI, 0.85–0.97; $P=0.006$). This effect was driven by a decrease in the carotid endarterectomy group (unadjusted odds ratio per year, 0.82; 95% CI, 0.73–0.92; $P=0.003$), whereas no significant decrease was found after carotid artery stenting (unadjusted odds ratio, 0.96; 95% CI, 0.88–1.04; $P=0.33$). Carotid endarterectomy patients had a lower procedural stroke or death risk compared with carotid artery stenting patients, and the difference significantly increased over time (interaction $P=0.031$). After adjustment for baseline characteristics, the results remained essentially the same.

CONCLUSIONS: The risk of stroke or death associated with carotid endarterectomy for symptomatic carotid stenosis decreased over an 8-year period, independent of clinical predictors of procedural risk. No corresponding reduction in procedural risk was seen in patients treated with stenting.

CLINICAL TRIAL REGISTRATION: URL: <https://www.clinicaltrials.gov>; <http://www.isrctn.com>. Unique identifier: NCT00190398 (EVA-3S), NCT00004732 (CREST), ISRCTN57874028 (SPACE), and ISRCTN25337470 (ICSS).

VISUAL OVERVIEW: A [visual overview](#) is available for this article.

Mandy D. Müller, MD
Stefanie von Felten, PhD
Ale Algra, MD
Jean-Pierre Becquemin, MD
Richard Bulbulia, MD
David Calvet, MD
Hans-Henning Eckstein, MD
Gustav Fraedrich, MD
Alison Halliday, MD
Jeroen Hendrikse, MD
George Howard, DrPH
John Gregson, PhD
Olav Jansen, MD
Martin M. Brown, MD*
Jean-Louis Mas, MD*
Thomas G. Brott, MD*
Peter A. Ringleb, MD*
Leo H. Bonati, MD*
for the Carotid Stenosis
Trialists' Collaboration

*Drs Brown, Mas, Brott, Ringleb, and Bonati contributed equally to this work as senior authors.

Key Words: carotid stenosis
■ endarterectomy ■ humans ■ risk factors ■ stents

© 2019 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circinterventions>



WHAT IS KNOWN

- Over past decades, stroke risk associated with carotid disease has declined, most likely reflecting improvements in medical therapy and better control of vascular risk factors.
- Whether the procedural risk associated with revascularization of carotid stenosis has also declined over time and whether any such temporal trend would differ between carotid endarterectomy and stenting was unclear.

WHAT THIS STUDY ADDS

- The risk of stroke or death associated with carotid revascularization in clinical trials has decreased over time.
- The decline in procedural risk was particularly apparent in patients treated with carotid endarterectomy.
- No significant decline in procedural risk was found with carotid artery stenting.

Over the past decades, the risk of stroke associated with carotid disease appears to have decreased,¹ reflecting improved medical care and risk factor control. In some patients, the risk of stroke under conservative management may be so low that the risks associated with carotid revascularization are no longer justified. This is of relevance for patients with asymptomatic carotid stenosis but potentially also for patients with symptomatic carotid stenosis. On the contrary, the procedural risk associated with carotid revascularization may also have decreased over time preserving the net benefit of invasive treatment. The evidence to support or refute such a trend is currently limited.

We conducted an analysis of the temporal change in procedural stroke or death risks associated with carotid endarterectomy (CEA) and carotid artery stenting (CAS) in the 4 large randomized controlled trials that enrolled patients with symptomatic carotid stenosis between 2000 and 2008, using data at individual patient level.^{2–5} We hypothesized that procedural risks associated with carotid artery revascularization would have declined over time. In addition, we assumed that risks of CAS might have decreased more strongly than CEA risks because of technical development and increasing experience.

METHODS

The data that support the findings of this study are available from the corresponding author on reasonable request. This meta-analysis includes individual patient data from EVA-3S (Endarterectomy Versus Angioplasty in Patients With

Symptomatic Severe Carotid Stenosis; unique identifier: NCT00190398), SPACE (Stent-Protected Angioplasty Versus Carotid Endarterectomy; unique identifier: ISRCTN57874028), CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial; unique identifier: NCT00004732), and ICSS (International Carotid Stenting Study; unique identifier: ISRCTN25337470).^{2–5} We excluded trials that included only asymptomatic stenosis, patients deemed at high risk from CEA, and those recruiting <300 patients. Ethics approval for the contributing trials was obtained at the competent institutional review boards, and all patients provided written informed consent. The pooled analysis of individual patient data was agreed on at the design stage of these trials. The present analysis was prespecified during one of the regular steering committee meetings of the Carotid Stenosis Trialists' Collaboration by representatives from the involved trials. All 4 trials randomly allocated patients with symptomatic moderate-to-severe carotid stenosis ($\geq 50\%$ reduction of lumen diameter measured according to the method used in NASCET [North American Symptomatic Carotid Endarterectomy Trial]⁶), who were equally suitable for either CAS or CEA and considered to be at standard procedural risk. The definition of symptomatic carotid stenosis was symptoms attributable to the relevant carotid artery within 120 days before randomization in EVA-3S, within 180 days before randomization in CREST, within 6 months before randomization in SPACE, and within 12 months before randomization in ICSS. CREST additionally included patients with asymptomatic carotid stenosis, but these patients were excluded from the present analysis.

In EVA-3S, SPACE, and ICSS, any stent with a Conformité Européenne mark could be used. In CREST, the protocol specified the use of RX Acculink stent. In EVA-3S the use of distal filter protection devices became mandatory early in the trial.⁷ In CREST, the protocol specified the use of the RX AccUNET embolic protection device whenever feasible. In ICSS and SPACE, the use of protection devices remained optional throughout the trials. Surgeons were allowed to perform standard or eversion endarterectomy under local or general anesthesia, with or without the use of shunts or patches.

The primary outcome of the present analysis was any stroke or death occurring within 30 days after treatment. Stroke was defined as an acute deficit of focal neurological function, which led to symptoms lasting >24 hours, resulting from intracranial vascular disturbance (ischemia or hemorrhage). Because the trials contributing to this analysis differed in assessment and definition of procedural myocardial infarction, we did not include myocardial infarction in the primary outcome.

Statistical Analysis

The analysis population included all patients in whom the randomly allocated treatment was initiated (per-protocol analysis).⁸ The following baseline characteristics of patients from all 4 source trials were summarized descriptively for an early (2000–2004) and a late enrollment period (2005–2008): sex, patient age, modified Rankin Scale (mRS) at baseline, systolic blood pressure at baseline, history of hypertension, diabetes mellitus, lipid-lowering therapy (LLT), smoking (past or present), coronary heart disease, degree of ipsilateral carotid

stenosis according to NASCET criteria,⁶ presence of contralateral carotid stenosis ($\geq 70\%$) according to NASCET criteria⁶ or occlusion, qualifying event (QE) type, and days from QE to treatment.

To investigate whether the risk of stroke or death within 30 days of treatment changed over time, we used generalized linear mixed-effects models with binomial error and logit link function, with a random intercept for each source trial. We fitted one generalized linear mixed-effects model for all patients, using treatment received (CAS versus CEA), year of treatment (as a continuous variable), and the interaction between treatment received and year of treatment as explanatory variables to investigate whether any difference in procedural risk between CAS and CEA changed over time. In addition, a separate generalized linear mixed-effects model with only year of treatment as explanatory variable was fitted for each treatment group separately. To adjust our models, we identified those baseline patient characteristics that were most strongly associated with procedural risk for stroke or death, using backward model selection based on Akaike information criterion, in all patients and in each treatment group separately. We continued dropping variables from the multivariate models as long as the Akaike information criterion for the reduced model was smaller than the Akaike information criterion of the former model. Because of the high percentage of missing values, we did not include days from QE to treatment in the backward model selection. The models investigating the effect of time on procedural risk were subsequently adjusted for all baseline characteristics selected in this manner. We performed a post hoc sensitivity analysis adjusting all models for days from QE to treatment. We defined an alpha level of 0.05 to ascribe statistical significance. No correction was made for multiple testing. All statistical analyses were performed as complete case analyses (no imputation of missing values), using the statistical software environment R (version 3.4.1; R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

In total, 4775 patients with symptomatic carotid stenosis were enrolled in the contributing trials. The pooled per-protocol analysis set included 4597 patients, 2271 of whom received CEA and 2326 CAS (Figure 1). EVA-3S enrolled patients from 2000 to 2005, SPACE from 2001 to 2006, ICSS from 2001 to 2008, and CREST from 2000 to 2008. Baseline characteristics were well balanced between treatment groups as previously reported.^{2–5} The proportions of patients with a history of hypertension, coronary heart disease, smoking, and severe ipsilateral carotid stenosis were significantly higher in the later enrollment period (2005–2008) compared with the early enrollment period (2000–2004; Table 1). The proportion of patients taking LLT significantly increased from 52.4% in the early enrollment period to 74.1% in the late enrollment period. Level of functional disability measured by the mRS was higher, and the time from QE to treatment was shorter in the late enrollment period (Table 1).

Crude percentages of patients with the primary outcome measure per year are shown in Table 2. In the CEA group, crude procedural risks were 7.1% between 2000 and 2002 and 2.0% between 2007 and 2008. In the CAS group, crude risks were 8.2% between 2000 and 2002 and 5.8% between 2007 and 2008 (Table 2). The risk of stroke or death during the procedural period for both treatments combined decreased significantly over time (unadjusted odds ratio [OR] per year, 0.91; 95% CI, 0.85–0.97; $P=0.006$). After adjustment for baseline characteristics, which were independently associated with the primary outcome in both treatment groups combined (age, mRS, hypertension, diabetes mellitus, and severe ipsilateral carotid stenosis; Table 1 in the [Data Supplement](#)), the decline in risk remained essentially unchanged (adjusted OR, 0.89; 95% CI, 0.83–0.95; $P<0.001$). In the post hoc sensitivity analysis additionally adjusting our models for days from QE to treatment, the results remained again essentially the same (OR, 0.91; 95% CI, 0.84–0.99; $P=0.023$).

In the CEA group alone, the risk of procedural stroke or death also decreased significantly over time, both in the unadjusted model (OR, 0.82; 95% CI, 0.73–0.92; $P=0.003$), in the model adjusted for mRS, hypertension, diabetes mellitus, coronary heart disease, ipsilateral severe carotid stenosis, and contralateral stenosis $>50\%$ or occlusion (OR, 0.82; 95% CI, 0.72–0.93; $P=0.002$), and in the model additionally adjusted for days from QE to treatment (OR, 0.81; 95% CI, 0.71–0.93; $P=0.005$).

In the CAS group alone, the change in procedural risk over time was not statistically significant in the unadjusted model (OR, 0.96; 95% CI, 0.88–1.05; $P=0.33$), in the model adjusted for age, hypertension, LLT, smoking, and QE type (OR, 0.95; 95% CI, 0.87–1.05; $P=0.28$), or in the model additionally adjusted for days from QE to treatment (OR, 0.95; 95% CI, 0.86–1.06; $P=0.38$).

Patients receiving CEA were at lower risk of procedural stroke or death than patients receiving CAS over the entire enrollment period (OR, 0.47; 95% CI, 0.35–0.62; adjusted for year of treatment; OR, 0.46; 95% CI, 0.35–0.62; adjusted for year of treatment, age, mRS at baseline, history of hypertension and diabetes mellitus, and severe ipsilateral carotid stenosis). This difference in procedural risk became more pronounced over time (unadjusted interaction: OR, 1.17; 95% CI, 1.02–1.35; $P=0.031$; adjusted interaction: OR, 1.16; 95% CI, 1.01–1.34; $P=0.038$; Figures 2 and 3). The interaction was of similar magnitude but no longer statistically significant when additionally adjusting for days from QE to treatment (OR, 1.13; 95% CI, 0.96–1.34; $P=0.142$).

DISCUSSION

In this meta-analysis of individual patient data from 4 randomized controlled trials, the risk of stroke




Figure 1. Study flowchart depicting all patients enrolled in the source trials included in meta-analysis, as well as events excluding patients from analysis.

CREST indicates Carotid Revascularization Endarterectomy Versus Stenting Trial; EVA-3S, Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis; ICSS, International Carotid Stenting Study; and SPACE, Stent-Protected Angioplasty Versus Carotid Endarterectomy.

or death associated with carotid revascularization for symptomatic carotid stenosis decreased significantly over time. When patients were analyzed separately by treatment, the decline in risk over time was only statistically significant in patients treated with CEA. This decrease in risk was independent of clinical risk factors.

Data from OxVasc (Oxford Vascular Study) showed a decline in age- and sex-specific stroke incidence in an unselected population in Oxfordshire, United Kingdom, between 1981 to 1984 and 2002 to 2004,⁹ coinciding with a significant increase in the use of blood pressure-lowering, antiplatelet-lowering, and lipid-lowering medication between the 2 periods. Likewise, meta-regression analyses suggested a decline in annual stroke risk associated with asymptomatic carotid stenosis over the past 20 years.¹ Indirect evidence on a decline in stroke risk in patients with symptomatic carotid stenosis can be gathered from transient ischemic attack registries: the 90-day stroke risk after a transient ischemic attack caused by large artery atherosclerosis was consistently reported to be around 20% in the last decade,^{10,11} but dropped to merely 6% in a recent publication.¹² While some of this decrease may probably have been accounted for by more rapid specialized assessment

and early carotid revascularization in selected patients, changes in medical therapy are also likely to be important. A study from Denmark of patients with symptomatic carotid stenosis found a decline in the rate of any recurrent cerebrovascular event before carotid revascularization from 29% to 2.5% after introduction of an optimized medical treatment regimen consisting of dual antiplatelet and statin therapy.¹³

In the original European and North American symptomatic CEA trials establishing the benefit of CEA in patients with symptomatic carotid stenosis, only a minority of patients received statins.¹⁴ Since these trials were conducted, medical therapy and risk factor management has improved, not only with more widespread use of statins but also with stricter control of blood pressure and management of other risk factors. A lower stroke risk under conservative management than observed in previous trials may obviate the need for invasive revascularization in many patients with symptomatic or asymptomatic carotid disease. On the contrary, any decline in the procedural risk of stroke or death associated with carotid revascularization would act toward maintaining the net benefit of invasive treatment. Existing literature suggests a decline

Table 1. Baseline Characteristics in the Early (2000–2004) and Late (2005–2008) Enrollment Period

	2000–2004 (n=2044)	2005–2008 (n=2553)	P Value
Male sex	69.8%	69.8%	0.995
Age, y (mean, SD)	69.2±9.4	69.3±9.1	0.669
Systolic blood pressure at baseline, mm Hg (mean, SD)	143.7±19.8	143.1±21.9	0.319
Hypertension	73.8%	77.0%	0.016
Diabetes mellitus	25.8%	24.4%	0.281
Lipid-lowering therapy	52.4%	74.1%	<0.001
Smoking (current or past)	62.0%	67.3%	<0.001
Coronary heart disease	26.2%	29.3%	0.025
mRS at baseline (median [IQR])	0 (0–1)	1 (0–1)	0.02
Degree of ipsilateral carotid stenosis			<0.001
Moderate (50%–69%)	22.4%	16.7%	
Severe (70%–99%)	77.6%	83.3%	
Contralateral stenosis or occlusion	14.5%	15.0%	0.648
Qualifying event type			0.063
Retinal ischemia	15.7%	18.3%	
Transient ischemic attack	37.9%	36.0%	
Hemispheric stroke	46.4%	45.8%	
Days from QE to treatment (median [IQR])*	32 (15–68)	26 (11–61)	<0.001

Baseline characteristics of patients enrolled in the 4 source trials during the early enrollment period (2000–2004) and the late enrollment period (2005–2008). *P* values for differences in baseline characteristics between the early and the late enrollment period were calculated using Welch test for continuous variables, Wilcoxon rank-sum test for mRS (not normally distributed), and χ^2 test for categorical variables. EVA-3S recorded LLT use at baseline, but patients were only considered to be taking LLT if started >3 mo before randomization. SPACE and CREST collected data on LLT use at randomization. ICSS did not collect information on LLT use at baseline but did collect these data at the 1-mo follow-up, which were included in the table. CREST indicates Carotid Revascularization Endarterectomy Versus Stenting Trial; EVA-3S, Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis; ICSS, International Carotid Stenting Study; IQR, interquartile range; LLT, lipid-lowering therapy; mRS, modified Rankin Scale; and SPACE, Stent-Protected Angioplasty Versus Carotid Endarterectomy.

*Date of the QE before randomization was not collected in SPACE initially, but for the pooled analysis, these dates were gathered where available. As a result, 16.6% of values for this variable are missing.

in procedural risk associated with CEA for asymptomatic carotid stenosis.¹⁵ However, reliable data on procedural risks for symptomatic carotid stenosis have been sparse,¹⁶ and it remained unknown whether temporal changes differed between CAS and CEA.

Our findings now provide strong evidence for a decline in procedural stroke or death risk associated with revascularization of symptomatic carotid stenosis over time. The availability of data at individual patient level from several randomized clinical trials yielded important strengths. First, we were able to show temporal changes with greater statistical power than was possible at the level of a single trial. Second, we were able to minimize the risk of confounding of the effect of time on procedural risk by a potential change in the characteristics of patients included in the trials during the course of enrollment. Some of the baseline risk factors that were associated with the procedural risk of stroke or death in both treatment groups combined (history of hypertension, disability measured by the mRS, and degree of ipsilateral carotid stenosis) became more prevalent in the later enrollment period. After adjusting for these risk factors, the results remained essentially the same.

A third strength of our study was that we were able to investigate whether any temporal trend in procedural risks would differ between CEA and CAS, owing to the randomized design of the source trials. Widespread use of CAS only started a few years before the start of the trials contributing to this meta-analysis. We, therefore, hypothesized that technical development and increasing experience would lead to a stronger decline in procedural risk with CAS compared with CEA. Surprisingly, we found the opposite to be true. It is possible that investigators became more selective in the patients they included in the trials as enrollment went on, in terms of characteristics that were not measured. If this was the case, any such selection effect must have had a stronger impact on procedural risks of CEA than on risks of CAS. Previous studies suggest that neurophysiological monitoring and intraoperative assessment of the treated carotid artery during the CEA procedure became more frequent over time and that these factors are associated with a lower short-term stroke or death risk.^{17,18} It is possible that these factors were also of importance in our study population, but the data were not available for the present analysis. For CAS, however, with growing experience, interventionists might have accepted

Table 2. Procedural Risk for Stroke or Death Expressed as Crude Risks Over Time

Year of Treatment	All Patients (n=4597)		Endarterectomy (n=2271)		Stenting (n=2326)	
	Patients, n	n (%)	Patients, n	n (%)	Patients, n	n (%)
2000–2002, n (%)	560	43 (7.7%)	280	20 (7.1%)	280	23 (8.2%)
2003, n (%)	659	43 (6.5%)	330	18 (5.5%)	329	25 (7.6%)
2004, n (%)	825	37 (4.5%)	411	13 (3.2%)	414	24 (5.8%)
2005, n (%)	919	58 (6.3%)	439	14 (3.2%)	480	44 (9.2%)
2006, n (%)	630	37 (5.9%)	310	13 (4.2%)	320	24 (7.5%)
2007–2008, n (%)	1004	39 (3.9%)	501	10 (2.0%)	503	29 (5.8%)
Total	4597	257 (5.6%)	2271	88 (3.9%)	2326	169 (7.3%)

Total numbers of patients recruited, as well as numbers of patients and crude percentages of patients with the primary outcome measure per year for all patients, patients treated with endarterectomy, and patients treated with carotid stenting separately. The years 2000 to 2003 and 2007 to 2008 were pooled because of the relatively small number of patients enrolled.


patients in the trials with more difficult anatomy, which may have counteracted any learning-curve effect.

The CREST investigators have previously reported a nonsignificant decline in the procedural stroke or death risk associated with CAS over time, and an initial decrease followed by an increase in CEA risk for which there was no conclusive explanation.¹⁹ Of note, CREST initially included only patients with symptomatic carotid stenosis but then additionally allowed patients with asymptomatic carotid stenosis in the trial during the course of enrollment. This change in the proportion of the 2 groups limited the investigation of a temporal trend. The present, pooled analysis specifically focused on temporal changes in treatment risks in patients with symptomatic carotid stenosis, considered to be at normal surgical risk. Therefore, data of patients with asymptomatic carotid stenosis enrolled in CREST were not incorporated. For the same reason, we did not include data from trials comparing stenting versus endarterectomy in asymptomatic patients only (ACT-1 [Asymptomatic Carotid Trial 1]) or in patients considered to be at elevated risk of procedural complications (SAPHIRE [Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy]).^{20,21} The combined analysis of data from 4 trials allowed for a more reliable investigation of temporal changes in treatment risks, and whether these differed between CAS and CEA, than was possible at the level of a single trial.

Embolus protection devices have been developed to prevent cerebral embolization during the CAS procedure, in an effort to reduce the procedural risk of stroke. Of note, the trials included in the present analysis differed in their policies on embolus protection device use; in the CREST trial, use of a single filter-type device was mandatory. In the EVA-3S, SPACE, and ICSS trials combined, embolus protection devices were used in 61% of patients treated with CAS (in 87% of cases, these were filter-type devices),²² but there was no significant difference in procedural stroke risk between patients treated with versus without an embolus protection device.

However, more recent types of protection devices, exerting arrest or reversal of flow across the stenosis, which may be more effective than filter devices in preventing stroke during CAS,^{23–26} were not widely used at the time of recruitment in these trials. Therefore, our study was not suited to detect an impact of such devices on stroke risk.

The question whether any change in procedural risk of carotid revascularization over time would be explained by an increased use of LLT was of particular interest. We found an increase of patients taking LLT from 52% in the early enrollment years to 74% in the late enrollment years. However, LLT did not explain procedural risk in the entire study population or in patients treated with CEA. LLT reduced procedural risk in patients treated with CAS, but the temporal change in CAS risk was not statistically significant either unadjusted or adjusted for LLT and other risk factors.

**Figure 2.** Decline in risk of stroke or death over time—unadjusted model.

Modeled risks of stroke or death occurring within 30 d after treatment over time by treatment group in the unadjusted generalized linear mixed-effects model. Open and closed circles represent fitted values from the model. Error bars represent Bayesian 95% credible intervals. The interaction between type of treatment and year of treatment was statistically significant (interaction $P=0.031$). CAS indicates carotid artery stenting; and CEA, carotid endarterectomy.




Figure 3. Decline in risk of stroke or death over time—adjusted model.

Modeled risks of stroke or death (fitted values) occurring within 30 d after treatment over time by treatment group in the adjusted generalized linear mixed-effects model. The fitted values are shown for a model patient with median age and modified Rankin Scale score at baseline, history of hypertension, and severe carotid stenosis but no history of diabetes mellitus. Open and closed circles represent fitted values from the model. Error bars represent Bayesian 95% credible intervals. The interaction between type of treatment and year of treatment was statistically significant (interaction $P=0.038$). CAS indicates carotid artery stenting; and CEA, carotid endarterectomy.

As both risk of stroke and procedural risk of revascularization appear to be lower than at the time of the initial CEA trials, substantial uncertainty remains as to which patients will still benefit from carotid revascularization in addition to contemporary medical therapy and risk factor management. Several randomized trials are currently investigating this question, including the ECST-2 (Second European Carotid Surgery Trial), the SPACE-2, the CREST-2, and the ACTRIS trials (Endarterectomy Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-Than-Average Risk of Ipsilateral Stroke). Of note, about 1 in 5 patients in our study population had moderate degree of stenosis (50%–69%). Degree of stenosis is but one of several factors known to predict stroke risk in patients with symptomatic carotid stenosis. Risk models including demographic factors, vascular risk factors, degree of stenosis, and plaque morphology help identify patients at high risk of stroke.²⁷ However, the use of such risk models was not specified in any of the contributing trials, and the selection of patients requiring revascularization was left to the discretion of the investigators.

Our study has important limitations. First, randomized trials provide data from highly selected centers, operators, and patients. Procedural stroke risks may be higher in a real-world setting. Thus the external validity of the absolute risks observed in our study is limited. However, as the protocols of the trials remained largely unchanged throughout the studies, we strongly believe that the observed decline in treatment risk is real and externally valid. Second, the trials included

in this meta-analysis were conducted between 2000 and 2008. The procedural risk associated with carotid revascularization methods might have declined even further since 2008. Particularly in CAS, the most recent technical developments, such as stent designs with small open area between struts,²⁸ reverse-flow protection systems,²³ and direct transcervical access,²⁹ were only achieved after completion of the 4 trials included in this meta-analysis, and many devices used in these trials are now outdated and no longer in use. Third, in the earliest years of enrollment (2000–2002), most patients included in this analysis were enrolled in either EVA-3S or SPACE. In addition, between 2007 and 2008, enrollment only continued in ICSS and CREST, whereas EVA-3S and SPACE had completed their enrollment. However, the adjustment for source trial included in all of our models should account for any differences between trials. In addition, in a post hoc analysis in which we excluded all patients from EVA-3S, the results remained essentially unchanged. Fourth, the results obtained in this analysis cannot necessarily be extrapolated to a decline in procedural risk outside of clinical trials. Finally, because of the high percentage of missing values, we did not include days from QE to treatment in our initial analysis even though this variable was shown to differentially influence the risk of carotid revascularization.³⁰

CONCLUSIONS

Treatment of symptomatic carotid stenosis within the examined trials became safer over time. The reduction in stroke or death risk over time was driven by a significant decline in procedural risks in patients treated with endarterectomy. Mechanisms underlying these findings remain to be determined.

ARTICLE INFORMATION

Received March 5, 2019; accepted June 4, 2019.

The Data Supplement is available at <https://www.ahajournals.org/doi/suppl/10.1161/CIRCINTERVENTIONS.119.007870>.

Correspondence

Martin M. Brown, MD, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom. Email martin.brown@ucl.ac.uk

Affiliations

Department of Neurology and Stroke Center (M.D.M. and L.H.B.) and Department of Clinical Research, Clinical Trial Unit (S.v.F.), University Hospital Basel, University of Basel, Switzerland. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus and Julius Center for Health Sciences and Primary Care (A.A.) and Department of Radiology (J.H.), University Medical Center Utrecht, Utrecht University, the Netherlands. Vascular Institute Paris East, Hôpital privé Paul D'Egine, Ramsay Group, Champsigny sur Marne, France (J.-P.B.). Clinical Trial Service Unit and Epidemiological Studies Unit (R.B.) and Medical Research Council Population Health Research Unit (R.B.), Nuffield Department of Population Health, University of Oxford, United Kingdom. Department of

Neurology, Hôpital Sainte-Anne, Université Paris-Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, France (D.C., J.-L.M.). Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University of Munich, Germany (H.-H.E.). Department of Vascular Surgery, Medical University of Innsbruck, Austria (G.F.). Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, United Kingdom (A.H.). Department of Biostatistics, UAB School of Public Health, Birmingham, AL (G.H.). Department of Medical Statistics, London School of Hygiene and Tropical Medicine, United Kingdom (J.G.). Clinic for Radiology and Neuroradiology, Universitätsklinikum Schleswig-Holstein Campus Kiel, Germany (O.J.). Department of Brain Repair and Rehabilitation, Stroke Research Centre, UCL Queen Square Institute of Neurology, University College London, United Kingdom (M.M.B., L.H.B.). Department of Neurology, Mayo Clinic, Jacksonville, FL (T.G.B.). Department of Neurology, University of Heidelberg Medical School, Germany (P.A.R.).

Acknowledgments

Drs Mas, Ringleb, and Bonati extracted individual patient data from the contributing trials. Dr von Felten performed the data analysis. Drs von Felten, Müller, and Bonati interpreted the data. Dr Müller wrote the first version of the manuscript. All authors made substantial contributions to conception and design of the study, acquisition of data, or analysis and interpretation of data, and were involved in revision of the manuscript. All authors gave the final approval to submit the manuscript for publication.

Sources of Funding

Dr Bonati was supported by grants from the Swiss National Science Foundation (PBB5B-116873), the University of Basel, Switzerland, and the Stroke Association. Dr Brown's Chair in Stroke Medicine at University College London is supported by the Reta Lila Weston Trust for Medical Research. Research of Dr Halliday is funded by the National Institute for Health Research Oxford Biomedical Research Center. G. Howard is funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke.

Disclosures

Dr Bonati has received an unrestricted research grant from AstraZeneca, as well as consultancy and advisory board fees from Amgen, Bayer, Bristol-Myers Squibb, and Claret Medical. Dr Ringleb has received lecture fees and advisory board fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Covedien, and Pfizer. The other authors report no conflicts.

REFERENCES

- Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. *Stroke*. 2010;41:e11–e17. doi: 10.1161/STROKEAHA.109.561837
- Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, Hennerici M, Stingele R, Fiehler J, Zeumer H, Jansen O. Results of the Stent-Protected Angioplasty Versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. *Lancet Neurol*. 2008;7:893–902. doi: 10.1016/S1474-4422(08)70196-0
- Mas JL, Arquizan C, Calvet D, Viguier A, Albucher JF, Piquet P, Garnier P, Viader F, Giroud M, Hosseini H, Hinzlin G, Favrole P, Hénon H, Neau JP, Ducrocq X, Padovani R, Milandre L, Rouanet F, Wolff V, Saudeau D, Mahagne MH, Sablot D, Amarenco P, Larrue V, Beyssen B, Leys D, Moulin T, Lieve M, Chatellier G; EVA-3S Investigators. Long-term follow-up study of endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis trial. *Stroke*. 2014;45:2750–2756. doi: 10.1161/STROKEAHA.114.005671
- Bonati LH, Dobson J, Featherstone RL, Ederle J, van der Worp HB, de Borst GJ, Mali WP, Beard JD, Cleveland T, Engelter ST, Lyrer PA, Ford GA, Dorman PJ, Brown MM; International Carotid Stenting Study Investigators. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. *Lancet*. 2015;385:529–538. doi: 10.1016/S0140-6736(14)61184-3
- Brott TG, Howard G, Roubin GS, Meschia JF, Mackey A, Brooks W, Moore WS, Hill MD, Mantese VA, Clark WM, Timaran CH, Heck D, Leimgruber PP, Sheffett AJ, Howard VJ, Chaturvedi S, Lal BK, Voeks JH, Hobson RW II; CREST Investigators. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. *N Engl J Med*. 2016;374:1021–1031. doi: 10.1056/NEJMoa1505215
- North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. *Stroke*. 1991;22:711–20.
- Mas JL, Chatellier G, Beyssen B; EVA-3S Investigators. Carotid angioplasty and stenting with and without cerebral protection: clinical alert from the endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial. *Stroke*. 2004;35:e18–e20. doi: 10.1161/01.STR.0000106913.33940.DD
- Bonati LH, Dobson J, Algra A, Branchereau A, Chatellier G, Fraedrich G, Mali WP, Zeumer H, Brown MM, Mas JL, Ringleb PA; Carotid Stenting Trialists' Collaboration. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. *Lancet*. 2010;376:1062–1073. doi: 10.1016/S0140-6736(10)61009-4
- Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P; Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). *Lancet*. 2004;363:1925–1933. doi: 10.1016/S0140-6736(04)16405-2
- Purroy F, Montaner J, Molina CA, Delgado P, Ribo M, Alvarez-Sabín J. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. *Stroke*. 2007;38:3225–3229. doi: 10.1161/STROKEAHA.107.488833
- Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. *Neurology*. 2004;62:569–573. doi: 10.1212/01.wnl.0000110311.09970.83
- Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Skoloudik D, Steg PG, Touboul PJ, Uchiyama S, Vicaute É, Wong LK; TIARegistry.org Investigators. One-year risk of stroke after transient ischemic attack or minor stroke. *N Engl J Med*. 2016;374:1533–1542. doi: 10.1056/NEJMoa1412981
- Shahidi S, Owen-Falkenberg A, Hjerpested U, Rai A, Ellemann K. Urgent best medical therapy may obviate the need for urgent surgery in patients with symptomatic carotid stenosis. *Stroke*. 2013;44:2220–2225. doi: 10.1161/STROKEAHA.111.000798
- Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, Warlow CP, Barnett HJ; Carotid Endarterectomy Trialists' Collaboration. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. *Lancet*. 2003;361:107–116. doi: 10.1016/S0140-6736(03)12228-3
- Munster AB, Franchini AJ, Qureshi MI, Thapar A, Davies AH. Temporal trends in safety of carotid endarterectomy in asymptomatic patients: systematic review. *Neurology*. 2015;85:365–372. doi: 10.1212/WNL.0000000000001781
- Rerkasem K, Rothwell PM. Temporal trends in the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis: an updated systematic review. *Eur J Vasc Endovasc Surg*. 2009;37:504–511. doi: 10.1016/j.ejvs.2009.01.011
- Kallmayer MA, Tsantilas P, Knappich C, Haller B, Storck M, Stadlbauer T, Kühn A, Zimmermann A, Eckstein HH. Patient characteristics and outcomes of carotid endarterectomy and carotid artery stenting: analysis of the German mandatory national quality assurance registry - 2003 to 2014. *J Cardiovasc Surg (Torino)*. 2015;56:827–836.
- Knappich C, Kuehn A, Tsantilas P, Schmid S, Breikreuz T, Kallmayer M, Zimmermann A, Eckstein HH. Intraoperative completion studies, local anesthesia, and antiplatelet medication are associated with lower risk in carotid endarterectomy. *Stroke*. 2017;48:955–962. doi: 10.1161/STROKEAHA.116.014869
- Howard G, Hopkins LN, Moore WS, Katzen BT, Chakhtoura E, Morrish WF, Ferguson RD, Hye RJ, Shawl FA, Harrigan MR, Voeks JH, Howard VJ, Lal BK, Meschia JF, Brott TG. Temporal changes in periprocedural events in the carotid revascularization endarterectomy versus stenting trial. *Stroke*. 2015;46:2183–2189. doi: 10.1161/STROKEAHA.115.008898
- Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Ansel G, Strickman NE, Wang H, Cohen SA, Massaro JM, Cutlip DE; SAPHIRE Investigators. Long-term results of carotid stenting versus endarterectomy in high-risk patients. *N Engl J Med*. 2008;358:1572–1579. doi: 10.1056/NEJMoa0708028
- Rosenfield K, Matsumura JS, Chaturvedi S, Riles T, Ansel GM, Metzger DC, Wechsler L, Jaff MR, Gray W; ACT I Investigators. Randomized trial of

- stent versus surgery for asymptomatic carotid stenosis. *N Engl J Med*. 2016;374:1011–1020. doi: 10.1056/NEJMoa1515706
22. Wodarg F, Turner EL, Dobson J, Ringleb PA, Mali WP, Fraedrich G, Chatellier G, Bequemin JP, Brown MM, Algra A, Mas JL, Jansen O, Bonati LH; Carotid Stenosis Trialists' Collaboration. Influence of stent design and use of protection devices on outcome of carotid artery stenting: a pooled analysis of individual patient data. *J Neurointerv Surg*. 2018;10:1149–1154. doi: 10.1136/neurintsurg-2017-013622
 23. Leal I, Orgaz A, Flores Á, Gil J, Rodríguez R, Peinado J, Criado E, Doblas M. A diffusion-weighted magnetic resonance imaging-based study of transcervical carotid stenting with flow reversal versus transfemoral filter protection. *J Vasc Surg*. 2012;56:1585–1590. doi: 10.1016/j.jvs.2012.05.107
 24. Castro-Afonso LH, Abud LG, Rolo JG, Santos AC, Oliveira Ld, Barreira CM, Velasco TR, Pontes-Neto OM, Abud DG. Flow reversal versus filter protection: a pilot carotid artery stenting randomized trial. *Circ Cardiovasc Interv*. 2013;6:552–559. doi: 10.1161/CIRCINTERVENTIONS.113.000479
 25. Mokin M, Dumont TM, Chi JM, Mangan CJ, Kass-Hout T, Sorkin GC, Snyder KV, Hopkins LN, Siddiqui AH, Levy EI. Proximal versus distal protection during carotid artery stenting: analysis of the two treatment approaches and associated clinical outcomes. *World Neurosurg*. 2014;81:543–548. doi: 10.1016/j.wneu.2013.10.031
 26. Omran J, Mahmud E, White CJ, Aronow HD, Drachman DE, Gray W, Abdullah O, Abu-Fadel M, Firwana B, Mishkel G, Al-Dadah AS. Proximal balloon occlusion versus distal filter protection in carotid artery stenting: a meta-analysis and review of the literature. *Catheter Cardiovasc Interv*. 2017;89:923–931. doi: 10.1002/ccd.26842
 27. Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. *Lancet*. 2005;365:256–265. doi: 10.1016/S0140-6736(05)17746-0
 28. Park KY, Kim DI, Kim BM, Nam HS, Kim YD, Heo JH, Kim DJ. Incidence of embolism associated with carotid artery stenting: open-cell versus closed-cell stents. *J Neurosurg*. 2013;119:642–647. doi: 10.3171/2013.5.JNS1331
 29. Plessers M, Van Herzele I, Hemelsoet D, Patel N, Chung EM, Vingerhoets G, Vermassen F. Transcervical carotid stenting with dynamic flow reversal demonstrates embolization rates comparable to carotid endarterectomy. *J Endovasc Ther*. 2016;23:249–254. doi: 10.1177/1526602815626561
 30. Rantner B, Kollerits B, Roubin GS, Ringleb PA, Jansen O, Howard G, Hendrikse J, Halliday A, Gregson J, Eckstein HH, Calvet D, Bulbulia R, Bonati LH, Becquemin JP, Algra A, Brown MM, Mas JL, Brott TG, Fraedrich G; Carotid Stenosis Trialists' Collaboration. Early endarterectomy carries a lower procedural risk than early stenting in patients with symptomatic stenosis of the internal carotid artery: results from 4 randomized controlled trials. *Stroke*. 2017;48:1580–1587. doi: 10.1161/STROKEAHA.116.016233